Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 14 de 14
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Acta Biochim Biophys Sin (Shanghai) ; 56(2): 270-279, 2024 02 25.
Artigo em Inglês | MEDLINE | ID: mdl-38282474

RESUMO

Previous studies have shown that puerarin plays a key role in protecting humans and animals from cardiovascular diseases. The exact mechanism of the therapeutic effect of puerarin on various cardiovascular diseases (protective effect on cardiomyocytes) is still unclear. In the present study, we identify the role of puerarin in an animal model of experimental heart failure (HF) and explore its underlying mechanisms. The HF rat model is induced by intraperitoneal injection of adriamycin (ADR), and puerarin is administered intragastrically at low, medium, and high concentrations. We demonstrate that puerarin significantly improves myocardial fibrosis and inflammatory infiltration and, as a result, improves cardiac function in ADR-induced HF rats. Mechanistically, we find for the first time that puerarin inhibits overactivated Na +/H + exchange isoform 1 (NHE1) in HF, which may improve HF by decreasing Na + and Ca 2+ ion concentrations and attenuating mitochondrial damage caused by calcium overload; on the other hand, puerarin inhibits the activation of the p38 pathway in HF, reduces the expressions of TGF-ß and proinflammatory cytokines, and suppresses myocardial fibrosis. In conclusion, our results suggest that Puerarin is an effective drug against HF and may play a protective role in the myocardium by inhibiting the activation of p38 and its downstream NHE1.


Assuntos
Cardiomiopatias , Doenças Cardiovasculares , Insuficiência Cardíaca , Isoflavonas , Humanos , Ratos , Animais , Cálcio/metabolismo , Doenças Cardiovasculares/metabolismo , Miocárdio/metabolismo , Insuficiência Cardíaca/tratamento farmacológico , Insuficiência Cardíaca/metabolismo , Cardiomiopatias/metabolismo , Fibrose
2.
Pharmacol Res ; 177: 106120, 2022 03.
Artigo em Inglês | MEDLINE | ID: mdl-35131482

RESUMO

CX-5461 is a first-in-class selective RNA polymerase I inhibitor. Previously we found that CX-5461 had anti-inflammatory activities. In this study we characterized potential immunosuppressive effects of CX-5461 and explored the underlying mechanisms. Allogeneic skin transplantation model (BALB/c to C57BL/6 mice) and heterotopic heart transplantation model (F344 to Lewis rats) were used. We showed that CX-5461 was a potent inhibitor of alloimmunity which prevented acute allograft rejections. CX-5461 treatment was invariably associated with expansion of the regulatory T cell population. In vitro, CX-5461 inhibited agonists-induced T cell activation. CX-5461 consistently inhibited the expression of interferon-γ and interleukin - 2, key mediators of T cell-mediated alloimmunity. Mechanistically, CX-5461-induced immunosuppression was, at least partly, dependent on the p53-DUSP5 (dual-specificity phosphatase 5) axis and subsequent antagonism of the Erk1/2 mitogen-activated protein kinase pathway. In conclusion, our results suggest that CX-5461 is a promising candidate of a novel class of immunosuppressant which may be used as an alternative to the currently approved anti-rejection therapies.


Assuntos
Imunossupressores , Proteína Supressora de Tumor p53 , Animais , Benzotiazóis , Fosfatases de Especificidade Dupla/genética , Imunossupressores/farmacologia , Camundongos , Camundongos Endogâmicos BALB C , Camundongos Endogâmicos C57BL , Naftiridinas , Ratos , Ratos Endogâmicos F344 , Ratos Endogâmicos Lew
3.
EMBO Rep ; 23(3): e53373, 2022 02 03.
Artigo em Inglês | MEDLINE | ID: mdl-34994492

RESUMO

Mammalian cells utilize Akt-dependent signaling to deploy intracellular Glut4 toward cell surface to facilitate glucose uptake. Low-density lipoprotein receptor (LDLR) is the cargo receptor mediating endocytosis of apolipoprotein B-containing lipoproteins. However, signaling-controlled regulation of intracellular LDLR trafficking remains elusive. Here, we describe a unique amino acid stress response, which directs the deployment of intracellular LDLRs, causing enhanced LDL endocytosis, likely via Ca2+ and calcium/calmodulin-dependent protein kinase II-mediated signalings. This response is independent of induction of autophagy. Amino acid stress-induced increase in LDL uptake in vitro is comparable to that by pravastatin. In vivo, acute AAS challenge for up to 72 h enhanced the rate of hepatic LDL uptake without changing the total expression level of LDLR. Reducing dietary amino acids by 50% for 2 to 4 weeks ameliorated high fat diet-induced hypercholesterolemia in heterozygous LDLR-deficient mice, with reductions in both LDL and VLDL fractions. We suggest that identification of signaling-controlled regulation of intracellular LDLR trafficking has advanced our understanding of the LDLR biology, and may benefit future development of additional therapeutic strategies for treating hypercholesterolemia.


Assuntos
Aminoácidos , Receptores de LDL , Aminoácidos/metabolismo , Animais , Proteínas de Transporte/metabolismo , Endocitose , Lipoproteínas/metabolismo , Fígado/metabolismo , Camundongos , Receptores de LDL/genética , Receptores de LDL/metabolismo
4.
Pharmacol Res ; 169: 105683, 2021 07.
Artigo em Inglês | MEDLINE | ID: mdl-34019981

RESUMO

Pathological vascular remodeling contributes to the development of restenosis following intraluminal interventions, transplant vasculopathy, and pulmonary arterial hypertension. Activation of the tumor suppressor p53 may counteract vascular remodeling by inhibiting aberrant proliferation of vascular smooth muscle cells and repressing vascular inflammation. In particular, the development of different lines of small-molecule p53 activators ignites the hope of treating remodeling-associated vascular diseases by targeting p53 pharmacologically. In this review, we discuss the relationships between p53 and pathological vascular remodeling, and summarize current experimental data suggesting that drugging the p53 pathway may represent a novel strategy to prevent the development of vascular remodeling.


Assuntos
Proteína Supressora de Tumor p53/metabolismo , Remodelação Vascular/efeitos dos fármacos , Animais , Humanos , Músculo Liso Vascular/efeitos dos fármacos , Músculo Liso Vascular/metabolismo , Músculo Liso Vascular/patologia , Transdução de Sinais/efeitos dos fármacos , Proteína Supressora de Tumor p53/efeitos dos fármacos
5.
Clin Pharmacol Ther ; 105(1): 201-209, 2019 01.
Artigo em Inglês | MEDLINE | ID: mdl-29672839

RESUMO

Development of nitrate tolerance is a major drawback to nitrate therapy. Prostacyclin (PGI2) is a powerful vasodilator produced from prostaglandin (PGH2) by prostacyclin synthase (PGIS) in endothelial cells. This study aimed to determine the role of PGIS S-nitrosylation in nitrate tolerance induced by nitroglycerin (GTN). In endothelial cells, GTN increased PGIS S-nitrosylation and disturbed PGH2 metabolism, which were normalized by mutants of PGIS cysteine 231/441 to alanine (C231/441A). Clearance of nitric oxide by carboxy-PTIO or inhibition of S-nitrosylation by N-acetyl-cysteine decreased GTN-induced PGIS S-nitrosylation. Enforced expression of mutated PGIS with C231/441A markedly abolished GTN-induced PGIS S-nitrosylation and nitrate cross-tolerance in Apoe-/- mice. Inhibition of cyclooxygenase 1 by aspirin, supplementation of PGI2 by beraprost, and inhibition of PGIS S-nitrosylation by N-acetyl-cysteine improved GTN-induced nitrate cross-tolerance in rats. In patients, increased PGIS S-nitrosylation was associated with nitrate tolerance. In conclusion, GTN induces nitrate cross-tolerance through PGIS S-nitrosylation at cysteine 231/441.


Assuntos
Sistema Enzimático do Citocromo P-450/metabolismo , Tolerância a Medicamentos/fisiologia , Oxirredutases Intramoleculares/metabolismo , Nitratos/metabolismo , Óxido Nítrico/metabolismo , Nitroglicerina/farmacologia , Idoso , Idoso de 80 Anos ou mais , Sequência de Aminoácidos , Animais , Bovinos , Cricetinae , Sistema Enzimático do Citocromo P-450/genética , Relação Dose-Resposta a Droga , Feminino , Células Endoteliais da Veia Umbilical Humana , Humanos , Oxirredutases Intramoleculares/genética , Masculino , Camundongos , Camundongos Knockout , Pessoa de Meia-Idade , Ratos , Ratos Sprague-Dawley , Vasodilatadores/farmacologia
6.
Clin Exp Hypertens ; 41(7): 657-661, 2019.
Artigo em Inglês | MEDLINE | ID: mdl-30311805

RESUMO

Backgrounds and aims: Increased arterial stiffness may increase cardiovascular morbidity and mortality. Angiotensin II type 1 receptor blockers (ARBs) are potentially useful in controlling the central blood pressure and arterial stiffness in mild to moderate essential hypertension, while the effects of ARBs in aged patients with essential hypertension are not entirely investigated. Methods: The carotid-femoral arterial pulse wave velocity (PWV) was measured in aged patients with essential hypertension. Results: In a cross-sectional study, PWV value was significantly higher in these old patients with essential hypertension, compared to patients without essential hypertension. In correlation analysis, PWV was associated positively with age, hypertension duration, and carotid atherosclerosis. However, there was no relationship between PWV and gender in aged patients with essential hypertension. In a perspective study, 6-12 months administration of ARBs (losartan, 50 mg/day; telmisartan, 40 mg/day; valsartan 80 mg/day; irbesartan, 150 mg/day) remarkably reduced PWV in aged patients with essential hypertension. Regression analyses of multiple factors indicated that the effects of ARBs on arterial stiffness were not associated with the reduction of blood pressure. Conclusion: ARB treatment is a negative risk factor of arterial stiffness in aged patients with essential hypertension.


Assuntos
Bloqueadores do Receptor Tipo 1 de Angiotensina II/farmacologia , Hipertensão Essencial/tratamento farmacológico , Rigidez Vascular/efeitos dos fármacos , Idoso , Idoso de 80 Anos ou mais , Bloqueadores do Receptor Tipo 1 de Angiotensina II/uso terapêutico , Aorta/fisiopatologia , Pressão Sanguínea/efeitos dos fármacos , Estudos Transversais , Hipertensão Essencial/fisiopatologia , Feminino , Humanos , Losartan/farmacologia , Masculino , Pessoa de Meia-Idade , Análise de Onda de Pulso , Telmisartan/farmacologia , Valsartana/farmacologia
7.
Clin Exp Hypertens ; 40(2): 192-201, 2018.
Artigo em Inglês | MEDLINE | ID: mdl-28872356

RESUMO

BACKGROUND: We have previously reported that the long-term exposure of organophosphorus induces vascular dementia (VD) in rats. As a coenzyme, vitamin B6 is mainly involved in the regulation of metabolisms. Whether vitamin B6 improves VD remains unknown. METHODS: The model of VD was induced by feeding rats with isocarbophos (0.5 mg/kg per two day, 12 weeks). The blood flow of the posterior cerebral artery (PCA) in rat was assessed by transcranial Doppler (TCD). The learning and memory were evaluated by the Morris Water Maze (MWM) test. RESULTS: Administration of vitamin B6 increased the blood flow in the right and left posterior cerebral arteries and improved the functions of learning and memory in isocarbophos-treated rats. Vitamin B6 increased the protein levels of N-methyl-D-aspartate receptor (NMDAR) 2B, postsynaptic densities (PSDs) protein 95, and calmodulin-dependent protein kinase II (CaMK-II) in the hippocampus, which were decreased by isocarbophos in rats. Morphological analysis by light microscope and electronic microscope indicated disruptions of the hippocampus caused by isocarbophos were normalized by vitamin B6. Importantly, the antagonist of NMDAR signaling by eliprodil abolished these beneficial effects produced by vitamin B6 on PCA blood flow, learning, memory, and hippocampus structure in rats, as well as the protein expression of NMDAR 2B, PSDs protein 95, and CaMK-II in the hippocampus. CONCLUSION: Vitamin B6 activates NMDAR signaling to prevent isocarbophos-induced VD in rats.


Assuntos
Demência Vascular/metabolismo , Demência Vascular/prevenção & controle , Receptores de N-Metil-D-Aspartato/metabolismo , Vitamina B 6/farmacologia , Complexo Vitamínico B/farmacologia , Animais , Proteína Quinase Tipo 2 Dependente de Cálcio-Calmodulina/metabolismo , Circulação Cerebrovascular/efeitos dos fármacos , Demência Vascular/induzido quimicamente , Proteína 4 Homóloga a Disks-Large/metabolismo , Antagonistas de Aminoácidos Excitatórios/farmacologia , Hipocampo/diagnóstico por imagem , Hipocampo/metabolismo , Hipocampo/ultraestrutura , Hipertensão/fisiopatologia , Malation/análogos & derivados , Masculino , Aprendizagem em Labirinto/efeitos dos fármacos , Memória/efeitos dos fármacos , Piperidinas/farmacologia , Artéria Cerebral Posterior/diagnóstico por imagem , Ratos , Ratos Sprague-Dawley , Transdução de Sinais/efeitos dos fármacos , Ultrassonografia Doppler
8.
Oncotarget ; 8(56): 95075-95082, 2017 Nov 10.
Artigo em Inglês | MEDLINE | ID: mdl-29221112

RESUMO

Traditional Chinese medication is increasingly used to treat a wide range of human chronic diseases like cardiovascular diseases and cancers. This study was designed to explore whether ka-sai-ping (KSP), a novel traditional Chinese medicine developed by us, prevents gastric cancer growths and to investigate the underlying mechanism. The xenograft model of mouse gastric cancer was established by injecting MFCs into nude mouse subcutaneously. Cell autophagy was assessed by MDC staining. Lysosome and mitochondria were detected by Lyso-Tracker Red and Mito-Traker Green staining. Incubation of cultured mouse gastric cancer cell line MFCs with KSP for 48 hours, concentration-dependently reduced cell survivals and activated autophagy, which were accompanied with damaged lysosomes and mitochondria. In vivo studies indicated that KSP therapy (20 ml/kg/day) for two weeks suppressed the growth of gastric cancer, increased the protein levels of LC3-II, beclin-1, cathepsin L, bcl-2, p53, and capase-3 in tumor tissues from the xenograft model of mouse gastric cancer. Importantly, all these effects induced by KSP were abolished by co-administration of autophagy inhibitor 3-MA. In conclusion, KSP activates cell autophagy to suppress gastric cancer growths. Clinically, KSP is potentially considered as a medicine to treat patients with gastric cancer.

9.
Sci Rep ; 7: 43508, 2017 03 02.
Artigo em Inglês | MEDLINE | ID: mdl-28252100

RESUMO

Endothelial dysfunction, which is caused by endothelial nitric oxide synthase (eNOS) uncoupling, is an initial step in atherosclerosis. This study was designed to explore whether Chinese medicine xin-mai-jia (XMJ) recouples eNOS to exert anti-atherosclerotic effects. Pretreatment of XMJ (25, 50, 100 µg/ml) for 30 minutes concentration-dependently activated eNOS, improved cell viabilities, increased NO generations, and reduced ROS productions in human umbilical vein endothelial cells incubated with H2O2 for 2 hours, accompanied with restoration of BH4. Importantly, these protective effects produced by XMJ were abolished by eNOS inhibitor L-NAME or specific eNOS siRNA in H2O2-treated cells. In ex vivo experiments, exposure of isolated aortic rings from rats to H2O2 for 6 hours dramatically impaired acetylcholine-induced vasorelaxation, reduced NO levels and increased ROS productions, which were ablated by XMJ in concentration-dependent manner. In vivo analysis indicated that administration of XMJ (0.6, 2.0, 6.0 g/kg/d) for 12 weeks remarkably recoupled eNOS and reduced the size of carotid atherosclerotic plaque in rats feeding with high fat diet plus balloon injury. In conclusion, XMJ recouples eNOS to prevent the growth of atherosclerosis in rats. Clinically, XMJ is potentially considered as a medicine to treat patients with atherosclerosis.


Assuntos
Aterosclerose/metabolismo , Medicamentos de Ervas Chinesas/farmacologia , Endotélio Vascular/efeitos dos fármacos , Endotélio Vascular/metabolismo , Óxido Nítrico Sintase Tipo III/metabolismo , Animais , Aterosclerose/tratamento farmacológico , Aterosclerose/etiologia , Aterosclerose/patologia , Biomarcadores , Sobrevivência Celular/efeitos dos fármacos , Citocinas/metabolismo , Dieta Hiperlipídica , Modelos Animais de Doenças , Endotélio Vascular/patologia , Perfilação da Expressão Gênica , Células Endoteliais da Veia Umbilical Humana , Humanos , Peróxido de Hidrogênio/farmacologia , Masculino , Medicina Tradicional Chinesa , Óxido Nítrico/biossíntese , Estresse Oxidativo/efeitos dos fármacos , Fosforilação , Placa Aterosclerótica/metabolismo , Placa Aterosclerótica/patologia , Ratos , Espécies Reativas de Oxigênio/metabolismo , Transdução de Sinais/efeitos dos fármacos , Transcriptoma
10.
J Cell Mol Med ; 20(4): 731-9, 2016 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-26818681

RESUMO

Vascular dementia, being the most severe form of vascular cognitive impairment (VCI), is caused by cerebrovascular disease. Whether organophosphorus causes VCI remains unknown. Isocarbophos (0.5 mg/kg per 2 days) was intragastrically administrated to rats for 16 weeks. The structure and function of cerebral arteries were assayed. The learning and memory were evaluated by serial tests of step-down, step-through and morris water maze. Long-term administration of isocarbophos reduced the hippocampal acetylcholinesterase (AChE) activity and acetylcholine (ACh) content but did not alter the plasma AChE activity, and significantly damaged the functions of learning and memory. Moreover, isocarbophos remarkably induced endothelial dysfunction in the middle cerebral artery and the expressions of ICAM-1 and VCAM-1 in the posterior cerebral artery. Morphological analysis by light microscopy and electron microscopy indicated disruptions of the hippocampus and vascular wall in the cerebral arteries from isocarbophos-treated rats. Treatment of isocarbophos injured primary neuronal and astroglial cells isolated from rats. Correlation analysis demonstrated that there was a high correlation between vascular function of cerebral artery and hippocampal AChE activity or ACh content in rats. In conclusion, chronic administration of isocarbophos induces impairments of memory and learning, which is possibly related to cerebral vascular dysfunction.


Assuntos
Disfunção Cognitiva/induzido quimicamente , Hipocampo/efeitos dos fármacos , Malation/análogos & derivados , Artéria Cerebral Média/efeitos dos fármacos , Praguicidas/toxicidade , Artéria Cerebral Posterior/efeitos dos fármacos , Acetilcolina/antagonistas & inibidores , Acetilcolina/metabolismo , Acetilcolinesterase/genética , Acetilcolinesterase/metabolismo , Animais , Astrócitos/efeitos dos fármacos , Astrócitos/metabolismo , Astrócitos/patologia , Circulação Cerebrovascular , Disfunção Cognitiva/genética , Disfunção Cognitiva/metabolismo , Disfunção Cognitiva/patologia , Expressão Gênica , Hipocampo/irrigação sanguínea , Hipocampo/metabolismo , Hipocampo/patologia , Molécula 1 de Adesão Intercelular/genética , Molécula 1 de Adesão Intercelular/metabolismo , Malation/toxicidade , Aprendizagem em Labirinto/efeitos dos fármacos , Memória/efeitos dos fármacos , Artéria Cerebral Média/metabolismo , Artéria Cerebral Média/patologia , Neurônios/efeitos dos fármacos , Neurônios/metabolismo , Neurônios/patologia , Artéria Cerebral Posterior/metabolismo , Artéria Cerebral Posterior/patologia , Cultura Primária de Células , Ratos , Molécula 1 de Adesão de Célula Vascular/genética , Molécula 1 de Adesão de Célula Vascular/metabolismo
11.
Exp Ther Med ; 8(1): 38-48, 2014 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-24944594

RESUMO

The aim of the present study was to evaluate the protective effect of the ultrafiltration extract of Xin Mai Jia (XMJ) on a human umbilical vein endothelial cell (HUVEC) injury model induced by hydrogen peroxide (H2O2), by providing experimental data to investigate the mechanism and efficacy underlying the therapeutic effects on atherosclerosis. HUVECs were first injured by H2O2 and then varying final concentrations of the Chinese herb extract were added. Effects of the XMJ extract on morphology, activity, monolayer permeability, biochemical indicators, cytokines, endothelial nitric oxide synthase (eNOS) protein content and eNOS gene expression in the HUVECs were analyzed. H2O2 significantly promoted HUVEC injury. The XMJ ultrafiltration extract significantly improved the morphological changes in the injured HUVECs. In addition, XMJ treatment increased cell activity and decreased monolayer permeability. The expression levels of intracellular adhesion molecule-1, vascular adhesion molecule-1, interleukin-1 and -6 and nuclear factor-κB decreased, while the expression levels of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 increased with XMJ administration. Increased levels of nitric oxide (NO), eNOS protein and eNOS gene expression were also observed. Therefore, the XMJ ultrafiltration extract exhibits marked anti-inflammatory effects and antioxidant abilities. These properties significantly inhibited the H2O2-induced injury of HUVECs, which may be associated with the NO-cyclic guanosine monophosphate signaling pathway.

12.
Exp Ther Med ; 7(1): 11-16, 2014 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-24348756

RESUMO

The aim of the present study was to explore whether an ultra-filtration extract from Xin Mai Jia (XMJ), a Chinese medicinal formulation, has a protective effect on human aortic smooth muscle cell (HASMC) injury models induced by hydrogen peroxide (H2O2), and to consider the mechanism and efficacy of the therapeutic action of XMJ on atherosclerosis. HASMCs were injured by H2O2 and then exposed to various concentrations of XMJ. The morphological changes, growth, proliferation, migration and cytokine release of HASMCs were detected using 2,3-bis-(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide (XTT), an enzyme-linked immunosorbent assay and a scratch adhesion test. H2O2 significantly promoted the proliferation of HASMCs. The ultra-filtration extract from XMJ was observed to significantly attenuate the morphological changes of injured HASMCs, reduce the expression levels of intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), interleukin (IL)-1, IL-6 and nuclear factor (NF)-κB, and increase the expression levels of matrix metalloproteinase (MMP)-2 and tissue inhibitor of metalloproteinase (TIMP). XMJ has clear anti-inflammatory and antioxidant effects, and significantly inhibits the proliferation and migration of HASMCs.

13.
Yao Xue Xue Bao ; 43(8): 806-10, 2008 Aug.
Artigo em Chinês | MEDLINE | ID: mdl-18956772

RESUMO

To detect the function and expression of ventricular M3 receptor (M3R) in cerebral-cardiac syndrome (CCS) model rats and to explore the relationship between the expression of M3R and the arrhythmia resulted from CCS, CCS model rats were induced by occluding right middle cerebral artery. ECG was monitored. Intracellular calcium ([Ca2+]i) changes after agitating M3R were recorded by laser scanning confocal microscope. Changes of M3R expression in the ventricular tissue were detected by Western blotting. QRS and QT intervals in CCS group were remarkably longer than that in sham group. According to the results of Western blotting, the level of M3R expression was remarkably lower in CCS group compared with that in the normal group. KCl induced [Ca2+]i increasing in CCS group could be depressed by choline and the effect of choline could be blocked by 4-DAMP. The lower expression of M3R in CCS group may be one of important reasons of arrhythmia resulted from CCS. M3R that depressed the [Ca2+]i increasing agitated by choline may become a new target to cure arrhythmia resulted from CCS.


Assuntos
Arritmias Cardíacas/metabolismo , Cálcio/metabolismo , Infarto da Artéria Cerebral Média/complicações , Receptor Muscarínico M3/metabolismo , Animais , Arritmias Cardíacas/etiologia , Arritmias Cardíacas/patologia , Arritmias Cardíacas/fisiopatologia , Colina/farmacologia , Eletrocardiografia , Ventrículos do Coração/metabolismo , Masculino , Antagonistas Muscarínicos/farmacologia , Miocárdio/metabolismo , Miocárdio/ultraestrutura , Miócitos Cardíacos/metabolismo , Piperidinas/farmacologia , Cloreto de Potássio/farmacologia , Distribuição Aleatória , Ratos , Ratos Wistar , Receptor Muscarínico M3/antagonistas & inibidores
14.
Cell Physiol Biochem ; 22(1-4): 147-56, 2008.
Artigo em Inglês | MEDLINE | ID: mdl-18769041

RESUMO

We have examined whether there is a close link between cerebral ischemia and arrhythmogenesis in rats as well as its possible electrophysiological mechanisms. Cerebral ischemic model was made by middle cerebral artery occlusion (MCAO). The incidence of electrocardiographic (ECG) abnormality was as high as 75.71% and the myocardium was severely damaged after MCAO 2 h. The normalized peak currents of I(Ca,L) in ventricular myocytes investigated by whole-cell patch clamp were larger in cerebral ischemic rats with arrhythmias than those in sham-operated rats. The steady-state inactivation curve of I(Ca,L) was shifted to more positive potentials and recovery of I(Ca,L) from inactivation was accelerated significantly, but the activation of I(Ca,L) was not influenced in cerebral ischemic rats with arrhythmias compared with control. Meanwhile the action potential duration (APD) of ventricular myocytes was prolonged obviously. The [Ca(2+)](i) induced by KCL in ventricular myocytes was also significantly increased by scanning confocal microscopy. Additionally, the mRNA and protein expression of alpha(1C)/Ca(V)1.2 detected by RT-PCR and immunohistochemistry analysis was also increased in myocardium of cerebral ischemic rats with arrhythmias. We conclude that the up-regulation in function and expression of L-type Ca(2+) channel as well as [Ca(2+)](i) increasing in cardiac myocytes of cerebral ischemic rats may provide mechanisms of arrhythmogenesis.


Assuntos
Arritmias Cardíacas/etiologia , Arritmias Cardíacas/metabolismo , Isquemia Encefálica/complicações , Isquemia Encefálica/metabolismo , Canais de Cálcio Tipo L/metabolismo , Miócitos Cardíacos/metabolismo , Potenciais de Ação/efeitos dos fármacos , Animais , Isquemia Encefálica/patologia , Cafeína/farmacologia , Cálcio/metabolismo , Canais de Cálcio Tipo L/genética , Infarto Cerebral/metabolismo , Eletrocardiografia , Regulação da Expressão Gênica/efeitos dos fármacos , Homeostase/efeitos dos fármacos , Infarto da Artéria Cerebral Média , Espaço Intracelular/efeitos dos fármacos , Espaço Intracelular/metabolismo , Ativação do Canal Iônico/efeitos dos fármacos , Cinética , Masculino , Miocárdio/patologia , Miocárdio/ultraestrutura , Miócitos Cardíacos/efeitos dos fármacos , Miócitos Cardíacos/ultraestrutura , Cloreto de Potássio/farmacologia , Subunidades Proteicas/genética , Subunidades Proteicas/metabolismo , Ratos , Ratos Wistar , Verapamil/farmacologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...